Immunovative Therapies initiates Phase IIb study of cancer vaccine to treat metastatic colorectal cancer
Immunovative Therapies' subsidiary ImmunoCare has reported the start of a Phase IIb study of CryoVax, a next-generation immunotherapy cancer vaccine product for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Colorectal Cancer | Immunotherapy | Pharmaceuticals | Study | Vaccines